GeneFerm Biotechnology Co., Ltd.

Total Valuation

GeneFerm Biotechnology Co., Ltd. carries a market capitalization of 1.52B, placing it among publicly traded companies globally. Its enterprise value stands at 2.13B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

GeneFerm Biotechnology Co., Ltd. currently has 41.46M shares outstanding.

Valuation Ratios

GeneFerm Biotechnology Co., Ltd. trades at a trailing price-to-earnings ratio of 89.76. The price-to-sales ratio is 4.07, and the price-to-book ratio stands at 4.31.

Enterprise Valuation

On an enterprise value basis, GeneFerm Biotechnology Co., Ltd. trades at an EV/EBITDA multiple of 54.45 and an EV/FCF ratio of 27.33. The EV/Sales ratio of 4.16 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 54.45 provides insight into valuation relative to core operating earnings.

Financial Position

GeneFerm Biotechnology Co., Ltd. maintains a current ratio of 3.75, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 39.70, indicating elevated leverage, while an interest coverage ratio of 8.39 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

GeneFerm Biotechnology Co., Ltd. posts a return on equity of 4.96 and a return on invested capital of 3.02.

Taxes

Over the trailing twelve months, GeneFerm Biotechnology Co., Ltd. has paid 4.42M in income taxes, reflecting an effective tax rate of 16.00.

Stock Price Statistics

GeneFerm Biotechnology Co., Ltd.'s stock has declined approximately -19.97817% over the past 52 weeks. The 50-day moving average sits at 37.77, while the 200-day moving average is 46.04.

Income Statement

Over the trailing twelve months, GeneFerm Biotechnology Co., Ltd. generated 511.50M in revenue and converted that into 23.21M in net income, yielding earnings per share of 0.54. EBITDA reached 39.07M, while operating income came in at 39.07M.

Balance Sheet

GeneFerm Biotechnology Co., Ltd. holds 280.26M in cash and equivalents against 324.23M in total debt, resulting in a net debt position of -41.72M. Total book value stands at 482.90M, with working capital of 436.85M providing operational flexibility.

Cash Flow

GeneFerm Biotechnology Co., Ltd. produced 53.35M in operating cash flow over the past twelve months. After subtracting -20.57M in capital expenditures, free cash flow totaled 32.77M - equivalent to 0.76 per share.

Margins

GeneFerm Biotechnology Co., Ltd. operates with a gross margin of 28.66, reflecting its pricing power and cost economics. The operating margin of 7.64 and net profit margin of 4.54 provide insight into operational efficiency.

Dividends & Yields

Scores

GeneFerm Biotechnology Co., Ltd. posts an Altman Z-Score of 3.68, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.